User profiles for J. Pater

Joe Pater

Professor of Linguistics, University of Massachusetts
Verified email at linguist.umass.edu
Cited by 7530

Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models

T Voskoglou-Nomikos, JL Pater, L Seymour - Clinical cancer research, 2003 - AACR
Purpose: We looked at the value of three preclinical cancer models, the in vitro human cell
line, the human xenograft, and the murine allograft, to examine whether they are reliable in …

Structure and substance in artificial‐phonology learning, part I: Structure

E Moreton, J Pater - Language and linguistics compass, 2012 - Wiley Online Library
Artificial analogues of natural‐language phonological patterns can often be learned in the
lab from small amounts of training or exposure. The difficulty of a featurally‐defined pattern …

Constraint conflict in cluster reduction

J Pater, JA Barlow - Journal of child language, 2003 - cambridge.org
… Dorsal-specific faithfulness is documented for onset selection in truncation in Pater (1997),
but we have yet to find a parallel case in onset selection in cluster reduction. This may be due …

[PDF][PDF] Interpreting the significance of changes in health-related quality-of-life scores

…, G Rodrigues, J Myles, B Zee, J Pater - Journal of clinical …, 1998 - academia.edu
Purpose: To determine the significance to patients of changes in health-related quality-of-life
(HLQ) scores assessed by the European Organization for Research and Treatment of …

[HTML][HTML] Erlotinib in lung cancer—molecular and clinical predictors of outcome

…, M Whitehead, K Ding, J Pater… - … England Journal of …, 2005 - Mass Medical Soc
Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

[HTML][HTML] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

…, P Therasse, MJ Palmer, JL Pater - … England Journal of …, 2003 - Mass Medical Soc
Background In hormone-dependent breast cancer, five years of postoperative tamoxifen
therapy — but not tamoxifen therapy of longer duration — prolongs disease-free and overall …

Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial

…, J Wunder, R Kandel, K Goddard, A Sadura, J Pater… - The Lancet, 2002 - thelancet.com
J Wunder and A Davis provided the prognostic variables used to describe the study sample,
… A Sadura, J Pater, and B Zee verified and analysed the data, and contributed to completion …

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17

…, DA Cameron, MJ Palmer, JL Pater - Journal of the …, 2005 - academic.oup.com
Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant
tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether …

Are long-chain polyunsaturated fatty acids essential nutrients in infancy?

M Makrides, M Neumann, K Simmer, R Gibson, J Pater - The Lancet, 1995 - Elsevier
We investigated whether the disparity in neural maturation between breastfed and formula-fed
term infants could be corrected by the addition of fish oil, a source of docosahexaenoic …

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

E Rapp, JL Pater, A Willan, Y Cormier… - Journal of Clinical …, 1988 - ascopubs.org
The survival benefit of combination chemotherapy to patients with advanced non-small-cell
carcinoma of the lung (NSCLC) is controversial. To study this question, the National Cancer …